A Prospective, Multicenter, Observational Cohort Study Assessing the Efficacy and Safety of Radiotherapy-sensitized Immunotherapy in Advanced Breast Cancer

Other illness

• Other conditions deemed unsuitable for inclusion in the study by the investigator.

Other

• Subjects with brain metastases or leptomeningeal metastases; if there are any suspected symptoms or signs of CNS involvement, they should be excluded by a cranial MRI scan;
• Have not signed the informed consent form;
• Pregnant or lactating women;

• Subjects are eligible for inclusion in the study only if all the following criteria apply:
• Men or women who are 18 years of age or older on the day of signing the informed consent;
• Patients with advanced breast cancer that is inoperable or has metastasized, confirmed by histology or cytology;
• Patients who, after MDT discussion at the metastatic breast cancer stage, are considered suitable for radiotherapy and have completed radiotherapy;
• Patients who have previously received and continue to use immunotherapy, or are planned to receive immunotherapy, and are scheduled to receive a systemic treatment regimen including immunotherapy as chosen by the physician within 3 weeks after completing radiotherapy;
• Patients with a traceable medical history during treatment;
• Subjects who are able to sign an informed consent to participate in the study.